i am unable to find the 2012 AASLD ifn lambda HBV eAg pos presentation, that
Jake Liang is referring to. This could mean that BMS will halt the entire development of ifn lambda, since the HCV market for interferon is likely to shrink dramatically in the near future.
it would be important to see the actual data on this. Jake placed the message in RED , that should mean it was pretty inferior.